Navigation Links
Micromet Announces Public Offering of Common Stock
Date:7/29/2009

BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole book running manager, with RBC Capital Markets as co-manager in this offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on June 19, 2009, which became effective on July 2, 2009. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
2. Micromet Added to Russell 3000 Index
3. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
4. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
5. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
6. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
7. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
8. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
9. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
10. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
11. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dallas, Texas (PRWEB) May 24, 2013 ... web-based benchmarking survey on kinase profiling carried out ... data, details of the breakdown of the responses ... for the future (2015). It also highlights some ... Research survey groupings. Two bottom-up models were developed ...
(Date:5/24/2013)... Quincy Bioscience, a leading research ... calcium-binding proteins to support healthy living, is pleased ... of apoaequorin in Food and Chemical ... British Industrial Biological Research Association. , The ... adverse effects, if any, of apoaequorin, in rats ...
(Date:5/23/2013)... N.Y. , May 23, 2013  BioScrip, Inc. ... Company will present at the Jefferies 2013 Global Healthcare ... Grand Hyatt New York. Richard ... Hai Tran , Chief Financial Officer, ... a.m. Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)... , May 23, 2013 PuraMed ... developer, and marketer of over-the-counter (OTC) medicinal and ... research opinion on the company based on low ... , Non-Prescription, All Natural Product to Treat ... Product Outperforms #1 Prescription Competitor , Currently ...
Breaking Biology Technology:Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3
... Diamyd Medical AB,( http://www.omxgroup.com, ticker: DIAM B; ... Medical permission to start a Phase III,clinical study in ... therapeutic,diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ... to be able to offer this,promising drug to our ...
... ROCKVILLE, Md., March 14 Human Genome,Sciences, Inc. (Nasdaq: ... the,Cowen and Company 28th Annual Health Care Conference will ... ., (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ), A ... present,a corporate overview on Wednesday, March 19, 2008 from ...
... March 14 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... Vice President and Chief Financial Officer, will present ... Conference in Boston at the,Boston Marriott Copley Place ... Time. A live webcast of the presentation can ...
Cached Biology Technology:Diamyd Gets Authorization to Begin Phase III Study in the US 2Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference 2
(Date:5/24/2013)... the world,s largest and fastest growing open-access publishers, today ... in Physics . , A broad scope journal covering ... an open-science and interactive web platform for the research ... , Frontiers, real-time and interactive peer-review enables fast, ... types. With an average of three months from submission ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... 284 million tons of cargo, transit the Panama Canal each ... the Panama Canal Authority. Each time a ship passes through, ... Gatun Lake, which is also a source of water for ... However, the advent of very large "super" cargo ships, now ... demanded change. The Panama Canal is being expanded to create ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3A new strategy required in the search for Alzheimer's drugs? 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... the human genome sequence annotation, high-throughput cloning methodologies, ... of Proteomics lead by Leonardo Brizuela (Harvard Medical ... mined public databases to collect the sequence information ... built a gene repository for this gene class. ...
... sake of five others may be the way to go ... building, but a Penn State Erie biologist is monitoring the ... animals and insects. , "I am currently doing research in ... wetlands to replace all the ones that were destroyed by ...
... suspected that fertilizer runoff from big farms can trigger ... ecosystems and even producing "dead zones" in the sea. ... the first direct evidence linking large-scale coastal farming to ... the March 10 issue of the journal Nature, the ...
Cached Biology News:Road salt affects mitigation wetlands 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 3Oceans more vulnerable to agricultural runoff than previously thought, study finds 4
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system, 220-240 V, uses ... proteins, oligonucleotides, carbohydrates, lipids, and other biomolecules ... applications. This system can generate high-density arrays ... slide or greater than 57,000 spots per ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
... have been developed for affinity capture ... variety of ProteinChip chemical surfaces allow ... their unique biochemical properties. Each chip ... sample comparison, and the chips are ...
Biology Products: